Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C5SS | ISIN: BMG889121031 | Ticker-Symbol: 0RP
Stuttgart
05.06.25 | 08:01
1,230 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TIZIANA LIFE SCIENCES LTD Chart 1 Jahr
5-Tage-Chart
TIZIANA LIFE SCIENCES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,2301,28011:13

Aktuelle News zur TIZIANA LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TIZIANA LIFE SCIENCES Aktie jetzt für 0€ handeln
23.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease346NEW YORK, May 23, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
23.05.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer2
15.05.Tiziana Life Sciences Ltd.: Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease325NEW YORK, May 15, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
15.05.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer1
12.05.Tiziana Chairman Gabriele Cerrone Boosts Stake To 37% With Share Purchase3
12.05.Tiziana Life Sciences reports purchase of shares by chairman3
12.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Purchase of Shares by Chairman226NEW YORK, May 12, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
09.05.Tiziana posts favorable PET scan data for lead asset in Alzheimer's1
09.05.Tiziana reports promising Alzheimer's treatment results1
09.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab289NEW YORK, May 09, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
08.05.Tiziana Life Sciences' intranasal MS candidate shows promise in open-label study1
06.05.Tiziana Life Sciences Ltd - 20-F, Annual and transition report of foreign private issuers1
06.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis231Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.All patients experienced stabilization of Expanded Disability...
► Artikel lesen
06.05.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer2
30.04.Why Tiziana Life Sciences Ltd (TLSA) is Surging in 20254
23.04.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial250NEW YORK, April 23, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully...
► Artikel lesen
23.04.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer3
02.04.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial398NEW YORK, April 02, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully...
► Artikel lesen
02.04.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer2
25.03.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial802NEW YORK, March 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully...
► Artikel lesen
Seite:  Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1